Efficacy of chloroquine and hydroxychloroquine for the treatment of hospitalized COVID-19 patients: a meta-analysis-Reference-Cited by-同舟云学术

Efficacy of chloroquine and hydroxychloroquine for the treatment of hospitalized COVID-19 patients: a meta-analysis

Published:2022-02 Issue:2 Volume:17 Page:95-118
ISSN:1746-0794
Container-title:Future Virology
language:en
Short-container-title:Future Virology

Author:

Deng Jiawen¹^ORCID,Zhou Fangwen¹^ORCID,Heybati Kiyan¹²^ORCID,Ali Saif¹^ORCID,Zuo Qi Kang³⁴^ORCID,Hou Wenteng¹^ORCID,Dhivagaran Thanansayan¹⁵^ORCID,Ramaraju Harikrishnaa Ba¹^ORCID,Chang Oswin¹^ORCID,Wong Chi Yi¹^ORCID,Silver Zachary⁶^ORCID

Affiliation:

1. Faculty of Health Sciences, McMaster University, 1280 Main St W, Hamilton, ON, L8S 4L8, Canada

2. Mayo Clinic Alix School of Medicine, Mayo Clinic, 200 1st St SW, Rochester, MN 55905, USA

3. Department of Anesthesiology, Rutgers, New Jersey Medical School, 185 S Orange Ave, Newark, NJ 07103, USA

4. Faculty of Science, McGill University, 845 Sherbrooke St W, Montreal, QC, H3A 0G5, Canada

5. Integrated Biomedical Engineering & Health Sciences Program (iBioMed), McMaster University, 1280 Main St W, Hamilton, ON, L8S 4L8, Canada

6. Faculty of Science, Carleton University, 1125 Colonel By Dr, Ottawa, ON, K1S 5B6, Canada

Abstract

Aims: To evaluate the efficacy and safety of hydroxychloroquine/chloroquine, with or without azithromycin, in treating hospitalized COVID-19 patients. Materials & methods: Data from randomized and observational studies were included in a random-effects meta-analysis. Primary outcomes included time to negative conversion of SARS-CoV-2 tests, length of stay, mortality, incidence of mechanical ventilation, time to normalization of body temperature, incidence of adverse events and incidence of QT prolongations. Results: Fifty-one studies (n = 61,221) were included. Hydroxychloroquine/chloroquine showed no efficacy in all primary efficacy outcomes, but was associated with increased odds of QT prolongations. Conclusion: Due to a lack of efficacy and increased odds of cardiac adverse events, hydroxychloroquine/chloroquine should not be used for treating hospitalized COVID-19 patients.

Publisher

Future Medicine Ltd

Subject

Virology

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fvl-2021-0119

Reference171 articles.

1. A comprehensive review of COVID-19 characteristics

2. Assessment of the SARS-CoV-2 basic reproduction number, R0, based on the early phase of COVID-19 outbreak in Italy

3. Rates of COVID-19-associated hospitalization in British Columbia and Ontario: time course of flattening the relevant curve

4. COVID-19 fatality rates in hospitalized patients: systematic review and meta-analysis

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Expert system-based application for fatal ventricular arrhythmia risk level estimation based on QT-Interval prolongation;Expert Systems with Applications;2024-12

2. Proarrhythmic major adverse cardiac events with donepezil: A systematic review with meta‐analysis;Journal of the American Geriatrics Society;2024-04-05

3. Computational repurposing of drugs for viral diseases and current and future pandemics;Journal of Mathematical Chemistry;2024-02-05

4. Pan-antiviral effects of a PIKfyve inhibitor on respiratory virus infection in human nasal epithelium and mice;Antimicrobial Agents and Chemotherapy;2024-01-10

5. Chiral distinction between hydroxychloroquine enantiomers in binding to angiotensin-converting enzyme 2, the forward receptor of SARS-CoV-2;Journal of Pharmaceutical and Biomedical Analysis;2024-01